Metachromatic Leukodystrophy - Competitive Landscape and Market Insights, 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Metachromatic Leukodystrophy - Competitive Landscape and Market Insights, 2018" report has been added to ResearchAndMarkets.com's offering.

Metachromatic Leukodystrophy - Competitive Landscape and Market Insights, 2018 provides comprehensive insights about pipeline drugs along with technologies involved across this indication. The report provides the detailed analysis of pipeline products along with the companies involved.

The report covers the Market Scenario till 2027, Attribute analysis, Product Potential Analysis, Metachromatic Leukodystrophy Market Evolution, and Unmet Needs. This report further provides comprehensive insights about the pipeline drugs. It covers all the clinical pipeline drug profiles and their comparative analysis along with forecasted sales for upcoming launches.

Products covered by Phase:

  • Phase III and Phase II
  • Pre-clinical and Discovery

Overview of pipeline development activities for Metachromatic Leukodystrophy

Pipeline analysis of the therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Key Topics Covered:

Overview

Causes

Pathophysiology

Types

Symptoms

Diagnosis

Treatment and Management

Epidemiology- 7MM

Key Findings

7MM

Assumptions and Rationale

Incidence of MLD in 7MM

Prevalence of MLD in 7MM

Competitive Landscape

Pipeline Scenario

GSK-2696274: GlaxoSmithKline

Product Description

Research and Development

Product Development Activities

GSK-2696274: Forecasted Sales

GSK-2696274: Analyst's Insights

Institutional Research

DUOC-01: Duke University Medical Center

Product Description

Research and Development

DUOC-01: Analyst's Insights

Market Assessment

7MM Market Size

Market Evolution

Attribute Analysis

Product Potential Analysis

Unmet Needs

Companies Mentioned

  • Recursion Pharmaceuticals
  • Shire
  • Armagen
  • GlaxoSmithKline

For more information about this report visit https://www.researchandmarkets.com/research/8hrfq2/metachromatic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs